Radiation Therapy
IMRT for Brain Cancer
Recruiting1 award3 criteria
Albuquerque, New Mexico
"This trial is comparing a newer type of radiation therapy called intensity modulated radiation therapy (IMRT) to the standard whole brain radiation therapy for treating brain metastases. The study aims to see if IM
Monoclonal Antibodies
Trastuzumab Emtansine Safety for Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial is for people who have been receiving treatment with either trastuzumab emtansine or a combination of it with other anti-cancer therapies, and who are still benefiting from the treatment. The purpose of the trial is to continue to monitor the safety of the treatment.
Kinase Inhibitor
LOXO-435 for Bladder Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing LOXO-435, a new drug, to see if it can help treat advanced cancers with a specific genetic change. It aims to block a gene that helps cancer cells grow. The study will check the drug's safety and effectiveness in these patients. LOX may be a potential effective therapeutic target to treat colorectal cancer.
Alkylating Agent
Abemaciclib + Chemotherapy for Sarcoma
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing whether adding a new drug called abemaciclib to standard cancer treatments can help children and young adults with Ewing's sarcoma that has come back or did not respond to previous treatments. Abemaciclib works by blocking proteins that help cancer cells grow, which may slow down or stop the tumor. Participation could last several months or more, depending on individual responses.
Popular Filters
Trials for Cancer Patients
Radiation Therapy
Laser Ablation + Radiosurgery for Spinal Cancer
Recruiting1 award
Detroit, Michigan
This trial is testing a new way to treat tumors near the spinal cord by combining two existing treatment methods. The goal is to improve tumor control and quality of life for patients with spinal metastasis.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
Recruiting1 awardPhase 1
Dallas, Texas
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Behavioural Intervention
Communication Intervention for Dementia
Recruiting1 award12 criteria
Seattle, Washington
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Chemotherapy
EMB-01 for Advanced Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
Trials for Adenocarcinoma Patients
Behavioural Intervention
Communication Intervention for Dementia
Recruiting1 award12 criteria
Seattle, Washington
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for HER2 Positive Patients
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
Recruiting1 awardPhase 1
Dallas, Texas
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Anti-metabolites
High-Dose Methotrexate for Breast Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing the use of high-dose methotrexate to treat leptomeningeal disease (LMD) in patients with metastatic breast cancer. LMD is a cancer that has spread to the thin layer of tissue that covers the brain and spinal cord. There is no cure for LMD, and it is a difficult disease to treat because it is hard to reach with traditional cancer treatments. HD-MTX is a chemotherapy drug that has been shown to be effective against breast cancer, and it is hoped that it will be effective against LMD as well. This study is being done to see if HD-MTX is
Diagnostic Test
MRI Screening for Brain Metastases in Breast Cancer
Recruiting1 award3 criteria
Toronto, Ontario
This trial will recruit 50 women with metastatic breast cancer to study the benefits of routine MRI screening for brain metastases. The participants will be randomly assigned to receive either regular brain MRI screening or the
Phase 3 Trials
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Monoclonal Antibodies
LY3537982 + Immunotherapy/Chemotherapy for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Tucson, Arizona
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Estrogen Receptor Antagonist
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Opioid Analgesic
Pain Medication for Postoperative Pain
Recruiting1 awardPhase 3
Saint Louis, Missouri
This trial is testing whether adding Toradol, an anti-inflammatory drug, to the usual opioid painkillers can better manage pain after surgery in patients who have had a specific type of bone surgery. These patients are chosen because they don't need the body's natural inflammation process for healing. Toradol works by reducing inflammation, while opioids change how the brain perceives pain. Toradol, also known as ketorolac, is a nonsteroidal anti-inflammatory drug (NSAID) that has been studied for its opioid-sparing effects in postoperative pain management.
Trials With No Placebo
Radiation Therapy
Laser Ablation + Radiosurgery for Spinal Cancer
Recruiting1 award
Detroit, Michigan
This trial is testing a new way to treat tumors near the spinal cord by combining two existing treatment methods. The goal is to improve tumor control and quality of life for patients with spinal metastasis.
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
Recruiting2 awardsPhase 3
Chandler, Arizona
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
Recruiting1 awardPhase 1
Dallas, Texas
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Behavioural Intervention
Communication Intervention for Dementia
Recruiting1 award12 criteria
Seattle, Washington
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Chemotherapy
EMB-01 for Advanced Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.